Clinical Trial Update: MRSI to Predict Response to RT/TMZ ± Belinostat in GBM [Phase 2]

View source ↗

Summary

Phase 2 trial investigating MR spectroscopy-guided response to radiotherapy and temozolomide with or without belinostat in glioblastoma multiforme.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Belinostat (belinostat)
• Radiotherapy
• Temozolomide (Temozolomide)

Snippet

Sponsor: Emory University | Conditions: Glioblastoma Multiforme of Brain | Phase 2 | Status: UNKNOWN